Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Deborah Donnell et al.|New England Journal of Medicine|2021Cited by 847
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L. Lennox, Peter Sklar, José Valdez Madruga et al.|The Lancet|2009Cited by 620